» Articles » PMID: 37366935

The Significance of Programed Cell Death-ligand 1 Expression in Vestibular Schwannoma

Overview
Journal Brain Behav
Specialty Psychology
Date 2023 Jun 27
PMID 37366935
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The association between programed cell death-ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) in vestibular schwannoma (VS) has been investigated in a few studies. These published studies report a difference in the PD-L1 positivity rate in malignant peripheral nerve sheath tumors. We examined PD-L1 expression and lymphocyte infiltration in patients with VS who had undergone surgical resection and investigated the association between PD-L1 expression and clinicopathological features.

Methods: The expression of PD-L1, CD8, and Ki-67 in 40 VS tissue specimens was investigated using immunohistochemistry, and a clinical review of the patients was performed.

Results: Of the 40 VS samples, 23 (57.5%) were positive for PD-L1 and 22 (55%) were positive for CD8. No significant differences in age, tumor size, pure-tone audiometry, speech discrimination, or Ki-67 expression were observed between patients in the PD-L1-positive and PD-L1-negative groups. A higher level of CD8-positive cell infiltration was observed in PD-L1-positive tumors than in PD-L1-negative tumors.

Conclusion: We demonstrated that PD-L1 was expressed in VS tissues. Although no correlation was identified between clinical characteristics and PD-L1 expression, the association between PD-L1 and CD8 was confirmed. Thus, additional research on targeting PD-L1 is necessary to improve immunotherapy for VS in the future.

Citing Articles

The significance of programed cell death-ligand 1 expression in vestibular schwannoma.

Lee S, Chin S, Jung S, Lee K, Moon K, Lee J Brain Behav. 2023; 13(9):e3137.

PMID: 37366935 PMC: 10498056. DOI: 10.1002/brb3.3137.

References
1.
Balar A, Weber J . PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother. 2017; 66(5):551-564. PMC: 11028560. DOI: 10.1007/s00262-017-1954-6. View

2.
Akinleye A, Rasool Z . Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019; 12(1):92. PMC: 6729004. DOI: 10.1186/s13045-019-0779-5. View

3.
Kyi C, Postow M . Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 2013; 588(2):368-76. DOI: 10.1016/j.febslet.2013.10.015. View

4.
Lee S, Chin S, Jung S, Lee K, Moon K, Lee J . The significance of programed cell death-ligand 1 expression in vestibular schwannoma. Brain Behav. 2023; 13(9):e3137. PMC: 10498056. DOI: 10.1002/brb3.3137. View

5.
Lee J, Lee J, Baek B, Lee B, Koh Y, Lee W . The inhibitory effect of honokiol, a natural plant product, on vestibular schwannoma cells. Laryngoscope. 2011; 122(1):162-6. DOI: 10.1002/lary.21781. View